IL92374A - Skin test and AIDS test kit - Google Patents

Skin test and AIDS test kit

Info

Publication number: IL92374A
Authority: IL; Israel
Prior art keywords: envelope protein; accordance; hiv; hiv envelope; protein
Prior art date: 1988-11-21

Application number

IL9237489A

Other languages

English (en)

Hebrew (he)

Other versions

IL92374A0 (en

Original Assignee

Microgenesys Inc West Haven

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-21

Filing date

1989-11-20

Publication date

1994-02-27

1989-11-20 Application filed by Microgenesys Inc West Haven filed Critical Microgenesys Inc West Haven

1990-07-26 Publication of IL92374A0 publication Critical patent/IL92374A0/xx

1994-02-27 Publication of IL92374A publication Critical patent/IL92374A/en

Links

238000012360 testing method Methods 0.000 title claims description 34
230000002163 immunogen Effects 0.000 claims abstract description 21
238000002347 injection Methods 0.000 claims abstract description 12
239000007924 injection Substances 0.000 claims abstract description 12
230000028993 immune response Effects 0.000 claims abstract description 4
230000008961 swelling Effects 0.000 claims abstract description 3
238000000034 method Methods 0.000 claims abstract 15
241000282412 Homo Species 0.000 claims abstract 2
101710091045 Envelope protein Proteins 0.000 claims description 27
101710188315 Protein X Proteins 0.000 claims description 27
239000000463 material Substances 0.000 claims description 26
108090000623 proteins and genes Proteins 0.000 claims description 19
102000004169 proteins and genes Human genes 0.000 claims description 15
241000238631 Hexapoda Species 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
241000700605 Viruses Species 0.000 claims description 6
239000000243 solution Substances 0.000 claims description 6
241000701447 unidentified baculovirus Species 0.000 claims description 6
230000001413 cellular effect Effects 0.000 claims description 5
230000001900 immune effect Effects 0.000 claims description 4
230000004044 response Effects 0.000 claims description 4
101800000385 Transmembrane protein Proteins 0.000 claims description 2
239000013598 vector Substances 0.000 claims description 2
102100021696 Syncytin-1 Human genes 0.000 claims 22
239000000203 mixture Substances 0.000 claims 8
239000007864 aqueous solution Substances 0.000 claims 2
235000019441 ethanol Nutrition 0.000 claims 2
230000000890 antigenic effect Effects 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract description 17
108010003533 Viral Envelope Proteins Proteins 0.000 abstract description 15
230000009385 viral infection Effects 0.000 abstract description 4
238000001514 detection method Methods 0.000 abstract 1
208000030507 AIDS Diseases 0.000 description 21
208000031886 HIV Infections Diseases 0.000 description 21
241000713772 Human immunodeficiency virus 1 Species 0.000 description 19
208000015181 infectious disease Diseases 0.000 description 10
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 8
230000005951 type IV hypersensitivity Effects 0.000 description 8
208000027930 type IV hypersensitivity disease Diseases 0.000 description 8
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 5
206010015150 Erythema Diseases 0.000 description 5
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 3
231100000321 erythema Toxicity 0.000 description 3
210000000245 forearm Anatomy 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
201000008827 tuberculosis Diseases 0.000 description 3
241000714195 Aids-associated retrovirus Species 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
208000002352 blister Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
108010041397 CD4 Antigens Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000008953 Cryptosporidiosis Diseases 0.000 description 1
206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010030154 Oesophageal candidiasis Diseases 0.000 description 1
208000007027 Oral Candidiasis Diseases 0.000 description 1
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
201000005655 esophageal candidiasis Diseases 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Immunology (AREA)
Dermatology (AREA)
Toxicology (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL9237489A 1988-11-21 1989-11-20 Skin test and AIDS test kit IL92374A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27419788A	1988-11-21	1988-11-21

Publications (2)

Publication Number	Publication Date
IL92374A0 IL92374A0 (en)	1990-07-26
IL92374A true IL92374A (en)	1994-02-27

Family

ID=23047193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9237489A IL92374A (en)	1988-11-21	1989-11-20	Skin test and AIDS test kit

Country Status (14)

Country	Link
EP (1)	EP0370573B1 (de)
JP (1)	JPH02262527A (de)
KR (1)	KR900007384A (de)
CN (1)	CN1043081A (de)
AT (1)	ATE126706T1 (de)
AU (1)	AU630129B2 (de)
BR (1)	BR8905851A (de)
CA (1)	CA2003300A1 (de)
DE (1)	DE68923932T2 (de)
DK (1)	DK582689A (de)
IL (1)	IL92374A (de)
LV (1)	LV10203B (de)
NO (1)	NO894614L (de)
ZA (1)	ZA898833B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6517843B1 (en)	1999-08-31	2003-02-11	Merial	Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6224882B1 (en)	1997-11-07	2001-05-01	Protein Science Corp.	Insect cells or fractions as adjuvant for antigens
JP2006516883A (ja)	2002-09-19	2006-07-13	アメリカ合衆国	Ｐ．アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
DE60327366D1 (de)	2002-10-29	2009-06-04	Fundacao Oswaldo Cruz	Lutzomyia longipalpis-polypeptide und verwendungsverfahren
EP2390352A1 (de)	2003-03-18	2011-11-30	Quantum Genetics Ireland Limited	Systeme und Methoden zur Erhöhung der Milchproduktion bei Tieren
US7468273B2 (en)	2003-05-01	2008-12-23	Meial Limited	Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en)	2003-11-13	2005-09-29	Brown Thomas P	Methods of characterizing infectious bursal disease virus
EP1718770B1 (de)	2004-02-19	2011-05-25	The Governors of the University of Alberta	Leptinpromotor-polymorphismen und verwendungen davon
RS51324B (sr)	2005-04-25	2010-12-31	Merial Ltd.	Vakcine protiv nipah virusa
US20080241184A1 (en)	2005-08-25	2008-10-02	Jules Maarten Minke	Canine influenza vaccines
CA2629522A1 (en)	2005-11-14	2007-05-18	Merial Limited	Gene therapy for renal failure
US7771995B2 (en)	2005-11-14	2010-08-10	Merial Limited	Plasmid encoding human BMP-7
US7862821B2 (en)	2006-06-01	2011-01-04	Merial Limited	Recombinant vaccine against bluetongue virus
US8202967B2 (en)	2006-10-27	2012-06-19	Boehringer Ingelheim Vetmedica, Inc.	H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US8603808B2 (en)	2008-05-08	2013-12-10	Merial Limited	Leishmania vaccine using sand fly salivary immunogen
CN103585643A (zh)	2009-04-03	2014-02-19	梅里亚有限公司	运载新城疫病毒的禽疫苗
TWI627281B (zh)	2009-09-02	2018-06-21	百靈佳殷格翰家畜藥品公司	降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
WO2012030720A1 (en)	2010-08-31	2012-03-08	Merial Limited	Newcastle disease virus vectored herpesvirus vaccines
AR083533A1 (es)	2010-10-22	2013-03-06	Boehringer Ingelheim Vetmed	Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (en)	2010-12-30	2012-07-05	The Netherlands Cancer Institute	Methods and compositions for predicting chemotherapy sensitivity
US20140296248A1 (en)	2011-04-04	2014-10-02	Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis	Methods and compositions for predicting resistance to anticancer treatment
AU2012240246A1 (en)	2011-04-04	2013-05-09	Netherlands Cancer Institute	Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2012145577A1 (en)	2011-04-20	2012-10-26	Merial Limited	Adjuvanted rabies vaccine with improved viscosity profile
AP2013007180A0 (en)	2011-04-25	2013-10-31	Advanced Bioscience Lab Inc	Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
EP2714077B1 (de)	2011-06-01	2018-02-28	Merial, Inc.	Nadellose verabreichung von prrsv-impfstoffen
BR112014001287B1 (pt)	2011-07-20	2020-12-08	Centre National De La Recherche Scientifique	vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
LT2741740T (lt)	2011-08-12	2017-08-10	Merial, Inc.	Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
AR088028A1 (es)	2011-08-15	2014-05-07	Boehringer Ingelheim Vetmed	Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en)	2011-09-03	2013-03-07	Boehringer Ingelheim Vetmedica Gmbh	Streptococcus suis pilus antigens
WO2013093629A2 (en)	2011-12-20	2013-06-27	Netherlands Cancer Institute	Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en)	2012-03-16	2013-09-19	Merial Limited	Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
ES2711878T3 (es)	2012-03-20	2019-05-08	Merial Inc	Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
WO2014127825A1 (en)	2013-02-21	2014-08-28	Boehringer Ingelheim Vetmedica Gmbh	H5 proteins of h5n1 influenza virus for use as a medicament
EP2968514A1 (de)	2013-03-12	2016-01-20	Merial, Inc.	Mittels reverser genetik hergestellte impfstoffzusammensetzungen gegen schmallenberg-virus und verfahren zur verwendung davon
CN112316129B (zh)	2014-04-03	2025-01-28	勃林格殷格翰动物保健美国有限公司	猪流行性腹泻病毒疫苗
WO2016073410A1 (en)	2014-11-03	2016-05-12	Merial, Inc.	Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
ES3050936T3 (en)	2015-06-23	2025-12-23	Boehringer Ingelheim Vetmedica Gmbh	Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
US9920302B2 (en)	2015-08-31	2018-03-20	Boehringer Ingelheim Vetmedica Gmbh	Pestivirus vaccines for congenital tremors
CA2996613A1 (en)	2015-09-16	2017-03-23	Boehringer Ingelheim Vetmedica, Inc.	Salmonella choleraesuis-salmonella typhimurium vaccines
AR109538A1 (es)	2016-09-20	2018-12-19	Boehringer Ingelheim Vetmedica Gmbh	Vacuna contra la gripe porcina
AU2017332677B2 (en)	2016-09-20	2024-01-11	Boehringer Ingelheim Vetmedica Gmbh	Canine adenovirus vectors
DK3516064T3 (da)	2016-09-20	2025-07-14	Boehringer Ingelheim Vetmedica Gmbh	Nye promotorer
CN109715204B (zh)	2016-09-20	2023-08-22	勃林格殷格翰动物保健有限公司	新的ehv插入位点orf70
EA201991065A1 (ru)	2016-11-03	2019-11-29		Вакцина против свиного парвовируса
AU2017353380B2 (en)	2016-11-03	2024-08-22	Boehringer Ingelheim Vetmedica Gmbh	Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
EP3573655A2 (de)	2017-01-30	2019-12-04	Boehringer Ingelheim Animal Health USA Inc.	Impfstoffe gegen porzines coronavirus
EP3651797A1 (de)	2017-07-12	2020-05-20	Boehringer Ingelheim Animal Health USA Inc.	Immunogene senecavirus-a-zusammensetzungen und verfahren dafür
KR20200057742A (ko)	2017-09-23	2020-05-26	베링거잉겔하임베트메디카게엠베하	파라믹소바이러스과 발현 시스템
WO2019092027A1 (en)	2017-11-09	2019-05-16	Boehringer Ingelheim Vetmedica Gmbh	Sapelovirus immunogenic compositions and uses thereof
CN111712575B (zh)	2018-02-23	2024-07-19	勃林格殷格翰动物保健有限公司	表达外源猫副粘病毒基因的重组病毒载体系统及由其制备的疫苗
AR115002A1 (es)	2018-03-19	2020-11-18	Boehringer Ingelheim Vetmedica Gmbh	Ehv con ul18 y/o ul8 inactivados
JP7245260B2 (ja)	2018-03-19	2023-03-23	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	Ｅｈｖ挿入部位ｕｌ４３
KR20260008832A (ko)	2018-03-26	2026-01-16	베링거 인겔하임 애니멀 헬스 유에스에이 인크.	면역원성 조성물의 제조방법
TW202026010A (zh)	2018-09-20	2020-07-16	德商百靈佳殷格翰維美迪加股份有限公司	抗豬流行性下痢之鼻內載體疫苗
TW202027785A (zh)	2018-09-20	2020-08-01	德商百靈佳殷格翰維美迪加股份有限公司	經修飾之pedv棘蛋白
US11858962B2 (en)	2020-02-06	2024-01-02	Boehringer Ingelheim Vetmedica Gmbh	Polypeptides useful for detecting anti-rhabdovirus antibodies
JP2023544396A (ja)	2020-10-05	2023-10-23	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	ロタウイルスに対するワクチン接種のために有用な融合タンパク質
WO2022076977A1 (en)	2020-10-05	2022-04-14	Boehringer Ingelheim Animal Health USA Inc.	Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8422513D0 (en) *	1984-09-06	1984-10-10	Wellcome Found	Immunodiagnostic methods
US4879212A (en) *	1986-04-02	1989-11-07	United Biomedical Inc.	Peptide composition and method for the detection of antibodies to HTLV-III
IL84154A0 (en) *	1986-10-16	1988-03-31	Microgenesys Inc	Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (ja) *	1986-12-15	1988-10-26	レプリゲン　コーポレーション	昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
ES2102347T3 (es) *	1987-02-20	1997-08-01	Genentech Inc	Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
EP0327801A1 (de) *	1988-01-08	1989-08-16	Deutsches Primatenzentrum Gesellschaft Mbh	HIV-2-Typ-Retrovirus von Primaten, Vakzine sowie diagnostische und pharmazeutische Zusammensetzungen

1989
- 1989-11-17 CA CA002003300A patent/CA2003300A1/en not_active Abandoned
- 1989-11-20 ZA ZA898833A patent/ZA898833B/xx unknown
- 1989-11-20 NO NO89894614A patent/NO894614L/no unknown
- 1989-11-20 DK DK582689A patent/DK582689A/da not_active Application Discontinuation
- 1989-11-20 DE DE68923932T patent/DE68923932T2/de not_active Expired - Fee Related
- 1989-11-20 AU AU45335/89A patent/AU630129B2/en not_active Ceased
- 1989-11-20 AT AT89202922T patent/ATE126706T1/de not_active IP Right Cessation
- 1989-11-20 JP JP1303048A patent/JPH02262527A/ja active Pending
- 1989-11-20 KR KR1019890016798A patent/KR900007384A/ko not_active Withdrawn
- 1989-11-20 EP EP89202922A patent/EP0370573B1/de not_active Expired - Lifetime
- 1989-11-20 IL IL9237489A patent/IL92374A/en not_active IP Right Cessation
- 1989-11-21 CN CN89109558A patent/CN1043081A/zh active Pending
- 1989-11-21 BR BR898905851A patent/BR8905851A/pt not_active Application Discontinuation
1993
- 1993-06-30 LV LVP-93-877A patent/LV10203B/xx unknown

Also Published As

Publication number	Publication date
CN1043081A (zh)	1990-06-20
LV10203B (en)	1995-04-20
NO894614L (no)	1990-05-22
AU4533589A (en)	1990-05-24
JPH02262527A (ja)	1990-10-25
EP0370573B1 (de)	1995-08-23
ATE126706T1 (de)	1995-09-15
AU630129B2 (en)	1992-10-22
NO894614D0 (no)	1989-11-20
EP0370573A2 (de)	1990-05-30
EP0370573A3 (de)	1991-08-14
CA2003300A1 (en)	1990-05-21
ZA898833B (en)	1990-08-29
DE68923932D1 (de)	1995-09-28
LV10203A (lv)	1994-10-20
DE68923932T2 (de)	1996-01-11
IL92374A0 (en)	1990-07-26
DK582689A (da)	1990-05-22
KR900007384A (ko)	1990-06-01
DK582689D0 (da)	1989-11-20
BR8905851A (pt)	1990-06-12

Legal Events

Date	Code	Title	Description
1996-09-12	RH	Patent void

Publication	Publication Date	Title
EP0370573B1 (de)	1995-08-23	Hauttest und Testkit für AIDS
Hollinshead et al.	1970	Skin-reactive soluble antigen from intestinal cancer-cell-membranes and relationship to carcinoembryonic antigens
Nerup et al.	1971	Antipancreatic cellular hypersensitivity in diabetes mellitus
Redfield et al.	1985	Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine: a cost reduction strategy
AU765050B2 (en)	2003-09-04	Immunodiagnostics using particle delivery methods
Neff et al.	1979	Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169
Gorse et al.	1996	A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine
JP3420245B2 (ja)	2003-06-23	ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
Viac et al.	1977	Specific immunity in patients suffering from recurring warts before and after repetitive intradermal tests with human papilloma virus
CZ295110B6 (cs)	2005-05-18	Nové peptidy odvozené z lidského proteinu tepelného šoku 60 pro léčbu diabetes mellitus, farmaceutické přípravky, způsoby léčení a diagnostické soupravy
Odaka et al.	1988	Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men
Torten et al.	1973	A new leptospiral vaccine for use in man. II. Clinical and serologic evaluation of a field trial with volunteers
Shawket et al.	1989	Selective suprasensitivity to calcitonin-gene-related peptide in the hands in Raynaud's phenomenon
Emmons et al.	1995	A modified ELISA and Western blot accurately determine anti-human immunodeficiency virus type 1 antibodies in oral fluids obtained with a special collecting device
Kelleher et al.	1997	Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection
Gorse et al.	1998	Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration
EP0230052B1 (de)	1994-04-06	Immunverstärker und verwandte Zusammensetzungen
Sommerville	1958	Epidemic Kerato-Conjunctivitis—an adenovirus infection
Bussiere et al.	1995	Preclinical safety assessment considerations in vaccine development
Powell et al.	1942	A rapid pertussis agglutination test
Björkholm et al.	1989	Immune status and booster effects of low doses of diphtheria toxoid in Swedish medical personnel
Hildreth et al.	1964	Alterations in delayed hypersensitivity produced by live attenuated measles virus in man
Hyöty et al.	1986	Cell‐mediated and humoral immunity to mumps virus antigen
Craven et al.	1994	Human Immunodeficiency Virus Infection in Pregnancy Epidemiology and Prevention of Vertical Transmission
Silverstone	1986	Generalised allergic reaction to human insulin